NYSE:BIOA - Bioamber Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.0128 -0.02 (-60.98 %)
(As of 07/23/2018 07:26 AM ET)
Previous Close$0.0310
Today's Range$0.0120 - $0.0290
52-Week Range$0.0120 - $2.88
Volume15.51 million shs
Average Volume2.97 million shs
Market Capitalization$3.08 million
P/E RatioN/A
Dividend YieldN/A
Bioamber logoBioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.

Receive BIOA News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry N/A


Debt-to-Equity Ratio0.24
Current Ratio1.08
Quick Ratio0.75


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.27 million
Price / Sales0.20
Cash FlowN/A
Price / CashN/A
Book Value$1.41 per share
Price / Book0.01


EPS (Most Recent Fiscal Year)N/A
Net Income$-22,470,000.00
Net Margins-238.43%
Return on Equity-48.72%
Return on Assets-22.92%


Outstanding Shares129,450,000
Market Cap$3.08

Bioamber (NYSE:BIOA) Frequently Asked Questions

What is Bioamber's stock symbol?

Bioamber trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIOA."

How were Bioamber's earnings last quarter?

Bioamber Inc (NYSE:BIOA) issued its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.02. The biotechnology company earned $2.50 million during the quarter, compared to analysts' expectations of $2.37 million. Bioamber had a negative net margin of 238.43% and a negative return on equity of 48.72%. View Bioamber's Earnings History.

What price target have analysts set for BIOA?

2 analysts have issued 12 month target prices for Bioamber's shares. Their forecasts range from $1.00 to $1.75. On average, they anticipate Bioamber's stock price to reach $1.3750 in the next twelve months. This suggests a possible upside of 10,642.2% from the stock's current price. View Analyst Ratings for Bioamber.

What is the consensus analysts' recommendation for Bioamber?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bioamber in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are Bioamber's key executives?

Bioamber's management team includes the folowing people:
  • Raymond J. Land, Chairman of the Board (Age 72)
  • Richard P. Eno, Chief Financial Officer, Director
  • Mario Settino, Chief Financial Officer
  • Michael A. Hartmann, Executive Vice President (Age 48)
  • James Millis, Chief Technology Officer (Age 59)
  • Robert Frost, Director
  • Kurt W. Briner, Independent Director (Age 70)
  • Heinz Haller, Independent Director (Age 62)
  • Ellen B. Richstone, Independent Director (Age 65)
  • Kenneth W Wall, Independent Director (Age 66)

Has Bioamber been receiving favorable news coverage?

News stories about BIOA stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bioamber earned a news impact score of 0.13 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.08 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Bioamber?

Shares of BIOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bioamber's stock price today?

One share of BIOA stock can currently be purchased for approximately $0.0128.

How big of a company is Bioamber?

Bioamber has a market capitalization of $3.08 million and generates $8.27 million in revenue each year. Bioamber employs 86 workers across the globe.

How can I contact Bioamber?

Bioamber's mailing address is 3850 Annapolis Ln N Ste 180, PLYMOUTH, MN 55447-5476, United States. The biotechnology company can be reached via phone at +1-612-7474423 or via email at [email protected]

MarketBeat Community Rating for Bioamber (NYSE BIOA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  278
MarketBeat's community ratings are surveys of what our community members think about Bioamber and other stocks. Vote "Outperform" if you believe BIOA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.